Janus Henderson Investors, an investment management company, released its “Janus Henderson Venture Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.

Sales of the ground-breaking cystic fibrosis (CF) drug Kaftrio was the main driver behind revenues of a Dublin unit of Vertex Pharmaceuticals surging to $2.63bn (€2.26bn) last year.

We propose a scalable graph processing hardware accelerator called NOVA that is based on a novel vertex management architecture that decouples the execution of reduction and propagation operations in ...

Lunar Vertex will be the first mission to carry out a comprehensive study of lunar magnetic anomaly and the associated swirl and mini-magnetosphere.

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet cell therapy ...

BOSTON & OSAKA, Japan, June 23, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license ...

About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions.

Ono and Vertex have entered into an exclusive collaboration and license agreement for povetacicept in Japan and South Korea Povetacicept is a therapeutic in development for multiple serious B ...

Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes.

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.